Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Casimersen and Golodirsen in Duchenne Muscular Dystrophy
NCT02500381Phase 3Completed
- Sponsor
- Sarepta Therapeutics
- Start
- Sep 2016
- Primary completion
- Nov 2024
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing SRP-4045 (Casimersen), SRP-4053 (Golodirsen) and Placebo → Active (3 arms). Primary endpoint: Change From Baseline in the 4-Step Ascend Velocity at 96 weeks. Started Sep 2016; status: completed.
02
Drugs
casimersengolodirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02500381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02500381.